Fresenius Kabi's ustekinumab biosimilar Otulfi ™ is now commercially available for both subcutaneous and intravenous formulations With this launch, Fresenius Kabi Canada's immunology biosimilar ...

Fresenius Kabi received Health Canada's Notice of Compliance (NOC) approval for Iodixanol injection on December 17 for both intravenous and intra-arterial administration With the launch of Iodixanol ...

Director and Head of Commercial, Fresenius Kabi Biopharma, Canada. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important role ...

Fresenius operates through two main business segments, Fresenius Kabi and Fresenius Helios. It owns investments in other healthcare businesses, most notably Fresenius Medical Care. Fresenius Kabi ...

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor ...

Aurora™ is the automated system that streamlines plasma collection, producing virtually cell-free plasma and providing an improved experience for both operators and donors. The system separates ...

The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Fresenius Kabi will be fully responsible for the marketing of Vifor’s intravenous iron portfolio in China.

Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering high-volume hemodiafiltration therapy to dialysis patients Introducing the 5008X CAREsystem and ...

Fresenius (FMS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

It’s the last day to book a flight on Southwest Airlines without being hit with a fee to check bags after the airline abandoned a decades-long luggage policy that executives once described as ...